Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial

Core Viewpoint - Actinogen Medical Limited's XanaMIA trial for Alzheimer's disease has been fully enrolled, with positive interim results leading to the continuation of the trial, and final results expected in November 2026 [1][3][9]. Company Developments - The independent Data Monitoring Committee (DMC) has recommended that the XanaMIA trial continue without amendments, indicating confidence in the safety and efficacy data reviewed [1][4]. - The trial involves 247 participants and aims to report topline final results in November 2026, with the last participant's evaluation visit expected in September 2026 [8][10]. - An open-label extension phase will allow participants to receive active Xanamem therapy for up to 25 months, providing additional long-term safety data [6][10]. Product Information - Xanamem (emestedastat) is a novel oral therapy designed to control cortisol levels in the brain, potentially slowing the progression of Alzheimer's disease and improving depressive symptoms [11]. - The drug has shown promising safety and efficacy in previous trials, with over 500 individuals treated to date [10]. Future Expectations - The company anticipates further key milestones in 2026, including the publication of results from the XanaCIDD phase 2a trial for major depressive disorder [5][7]. - Actinogen expects to receive scientific advice from the European Medicines Agency regarding its Alzheimer's development program in the second quarter of 2026 [7].